Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COYA 201
- Development stage
- Unknown
- Lead developer
- Coya Therapeutics
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
COYA 201 is an autologous regulatory T-cell (Treg)-derived exosome therapy being developed by Coya Therapeutics for the treatment of neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS). The therapy utilizes exosomes—small extracellular vesicles—secreted by a patient's own Tregs. These exosomes are designed to deliver anti-inflammatory and neuroprotective signals to the central nervous system, aiming to modulate the neuroinflammatory environment characteristic of ALS. The technology was licensed from The Methodist Hospital and is part of Coya's broader Treg-based platform.
- Other names
- autologous Treg-derived exosome
Beyond the preview
Go deeper on COYA 201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COYA 201.